Michael J. Rosen, MD, MSCI

Attending Physician, Division of Gastroenterology, Hepatology and Nutrition

Physician, Schubert-Martin Inflammatory Bowel Disease Center

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-7044

Email michael.rosen@cchmc.org


Pediatric gastroenterology; pediatric inflammatory bowel disease


Mucosal immunology; epithelial biology; clinical pharmacology

Michael J. Rosen, MD, MSCI, focuses his career on the clinical care of children with inflammatory bowel disease (IBD), and to research aimed at better understanding the causes of chronic inflammation in childhood IBD. The primary focus of Dr. Rosen's laboratory is on the contribution of type 2 (th2) inflammation to pediatric colitis. Studies from Dr. Rosen’s lab have elucidated the roles of the type 2 transcription factor STAT6 and the type 2 cytokine IL-33 in ulcerative colitis. Dr. Rosen also leads an ongoing multi-center study to identify determinants of response to anti-TNF therapy in children hospitalized with acute severe ulcerative colitis.

Dr. Rosen's research has been funded by the National Institutes of Health, the Crohn's & Colitis Foundation of America (CCFA), the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), and the American College of Gastroenterology. Dr. Rosen serves on the editorial board of the journal Inflammatory Bowel Diseases. He is co-chair of the the Pediatric Affairs Committee for the CCFA and serves on the CCFA National Scientific Advisory Committee. His a past recipient of the NASPGHAN Fellow to Faculty Transition Award in IBD and the George Ferry Young Investigator Award.

MD: Harvard Medical School, Boston, MA, 2003.

Residency: Boston Combined Residency Program in Pediatrics (Boston Children's Hospital and Boston Medical Center), Boston, MA, 2003-2006.

Fellowship: Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center and the Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2006-2009.

Masters of Science in Clinical Investigation (MSCI): Vanderbilt University School of Medicine, Nashville, TN, 2009.

Certification: Pediatrics, 2007; Pediatric Gastroenterology, Hepatology and Nutrition, 2009.

View PubMed Publications

Waddell A, Vallance JE, Moore PD, Hummel AT, Shanmukhappa SK, Wu D, Fei L, Washington MK, Minar P, Coburn L, Nakae S, Wilson KT, Denson LA, Hogan SP, Rosen MJ. IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function. Inflammatory Bowel Diseases. 2015; 21(12):2737-46.

Rosen MJ, Minar P, Vinks AA. Review Article: Applying Pharmacokinetics to Optimize Dosing of Anti-TNF Biologics in Acute Severe Ulcerative Colitis. Alimentary Pharmacology and Therapeutics. 2015;41(11):1094-103.

Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatrics. 2015;169(11):1053-60.

Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ. Outcome following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2014; 58(2):213-9.

Rosen MJ*, Chaturvedi R, Washington MK, Kuhnhein LA, Moore PD, Coggeshall SS, McDonough EM, Weitkamp JH, Singh AB. Coburn LA, Williams CS, Van Kaer L, Peebles RS, Wilson KT. STAT6 activation intensifies disease severity while increasing expression of claudin-2 and Th2-inducing cytokines in murine oxazolone colitis. The Journal of Immunology. 2013; 190(4):1849-1858.

Rosen MJ*, Frey MR, Washington MK, Chaturvedi R, Kuhnhein LA, Matta P, Revetta F, Wilson KT, Polk DB. STAT6 activation in ulcerative colitis: A new target for prevention of IL-13-induced colonic epithelial cell dysfunction. Inflammatory Bowel Diseases. 2011; 17(11):2224-2234.

Rosen MJ, Moulton DE, Koyama T, Morgan WM, Morrow SE, Herline AJ, Muldoon RL, Wise PE, Polk DB, Schwartz DA. Endoscopic Ultrasound to Guide the Combined Medical and Surgical Management of Pediatric Perianal Crohn’s Disease. Inflammatory Bowel Diseases. 2010; 16(3):461-8.

Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122.

Sands BE, Arsenault JE, Rosen MJ, et al. Risk of Early Surgery for Crohn's Disease: Implications for Early Treatment Strategies. American Journal of Gastroenterology. 2003;98(12):2712-2718.

Th2 Cytokines and Signaling in Pediatric Inflammatory Bowel Disease. Principal Investigator. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK). Mar 2013-Mar 2018.

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children (ARCH). Principal Investigator. Broad Medical Research Program at the Crohn's & Colitis Foundation of America. Mar 2016–Feb 2018.

Impact of ST2 Signaling and IBD Risk Variants on the Intestinal Epithelium. Principal Investigator. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) R03. Jun 2016–May 2018.